U.S. Securities and Exchange Commission
Washington, D.C. 20549
Form 10-KSB/A
ANNUAL REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For fiscal year ended April 30, 1996
Commission File Number
0-20424
--------------------------
Hi-Tech Pharmacal Co., Inc.
----------------------------------------------
(Name of small business issuer in its charter)
New York 11-2638720
- ------------------------------- -----------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification
incorporation or organization) Number)
369 Bayview Avenue, Amityville, New York 11701
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(516) 789-8228
-----------------------------
Issuer's telephone number
Securities registered under Section 12(b) of the Exchange Act: None
Securities registered under Section 12(g) of the Exchange Act:
Common Stock, $.01 par value
- ----------------------------
(Title of Class)
Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes X No
---- ----
Check if there is no disclosure of delinquent filers in response to
Item 405 of Regulation S-B contained in this form, and no disclosure will be
contained, to the best of the registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. (X)
The issuer's revenues for its most recent fiscal year ended April 30, 1996 were
$19,140,000.
The aggregate market value of the voting stock held by non-affiliates of the
issuer on July 22, 1996, based upon the price at which such stock was sold on
that date, was $18,408,000. The number of shares of Common Stock of the issuer
outstanding as of July 22, 1996 was 4,475,707.
Transitional Small Business Disclosure Format: Yes No X
---- ----
<PAGE>
SIGNATURE
In accordance with Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
Dated: September 10, 1996
HI-TECH PHARMACAL CO., INC.
By: /s/Bernard Seltzer
_____________________________
Bernard Seltzer,
Chairman of the Board,
Chief Executive Officer,
President
By: /s/Arthur S. Goldberg
______________________________
Arthur S. Goldberg,
Chief Financial Officer
2
WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0000887497
<NAME> Hi-Tech Pharmacal Co., Inc.
<MULTIPLIER> 1000
<CURRENCY> U.S. Dollars
<S> <C>
<PERIOD-TYPE> 12-MOS
<FISCAL-YEAR-END> APR-30-1996
<PERIOD-START> MAY-01-1995
<PERIOD-END> APR-30-1996
<CASH> 1,746
<SECURITIES> 0
<RECEIVABLES> 3,859
<ALLOWANCES> (160)
<INVENTORY> 3,646
<CURRENT-ASSETS> 479
<PP&E> 13,507
<DEPRECIATION> (2,909)
<TOTAL-ASSETS> 20,234
<CURRENT-LIABILITIES> 4,406
<BONDS> 0
0
0
<COMMON> 45
<OTHER-SE> 13,126
<TOTAL-LIABILITY-AND-EQUITY> 20,234
<SALES> 19,140
<TOTAL-REVENUES> 19,140
<CGS> 11,785
<TOTAL-COSTS> 5,534
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 149
<INCOME-PRETAX> 2,206
<INCOME-TAX> 871
<INCOME-CONTINUING> 1,335
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 1,335
<EPS-PRIMARY> $0.29
</TABLE>
